Compared with the finance sector, pharma's adoption of big data is still at an embryonic stage. The potential is, however, massive. If caution is given evolving legal frameworks, and data protection respected, it could ultimately transform the industry's functionality at every level.
Beverley Flynn, Commercial Partner at Stevens & Bolton LLP writes for European Pharmaceutical Contractor on this subject. Click here for a copy of the full article which features in the digital version and will later this month be published in the print version of the publication.